0

Close
 
Upcoming Allied Market Research
2023
Aplastic Anemia Treatment Market

Aplastic Anemia Treatment Market

by Treatment Type (Bone Marrow Transfusion/Stem Cell Therapy, Blood Transfusion, Drug Therapy), by Disease Type (Acquired Aplastic Anemia, Inherited Aplastic Anemia), by End User (Hospitals, Research Institutes, Others) and by Route of Administration (Intravenous, Oral): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A11661
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Aplastic Anemia Treatment Market

Request Now !

Aplastic anemia occurs when the body stops producing enough new blood cells. Patients who suffer from this condition feel more fatigued than normal and are more prone to uncontrolled bleeding and infections. It is a rare and serious condition that can develop at any age. Aplastic anemia can happen slowly and worsen over time or occur suddenly. Treatment of aplastic anemia often includes medications, blood transfusions, or stem cell transplants, also called bone marrow transplant. The most common cause of this condition is autoimmunity. However, other factors that can injure bone marrow include radiation and chemotherapy, exposure to toxic chemicals, and parvovirus infections.

Aplastic-Anemia-Treatment

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

However, with COVID-19, the supply chain of raw material required to manufacture drugs to treat aplastic anemia has been disrupted in many countries. In addition, the market growth for aplastic anemia treatment is also declining as manufacturers of these drugs have slowed down their production, owing to the pandemic. This, in turn, is expected to have a significant impact on the aplastic anemia treatment market.

Top Impacting Factors

  • Increase in prevalence of blood disorders across the globe is anticipated to positively influence the global aplastic anemia treatment market during the forecast period.
  • Rise in awareness of conditions such as aplastic anemia and other related blood disorders can also fuel growth of the market. With increase in awareness patients can seek necessary treatments and therapies that can help their conditions with aplastic anemia get better.
  • With a rise in population and increase in disposable income in developed nations, consumers tend to have better purchasing power, owing to which they can invest in best treatment options for aplastic anemia. This, in turn, is expected to propel the aplastic anemia treatment market growth.
  • High cost of treatment options for aplastic anemia hinders growth of the aplastic anemia treatment market in developing nations. For instance, cost of a bone marrow transplant is around $300,000, which is unaffordable for many patients.

Key Market Trends

In November 2018, the Food and Drug Administration (FDA) approved Promacta, which is the first-line treatment for aplastic anemia. It was launched by Novartis AG. Novartis AG also received approval for Revolade, which is used for aplastic anemia treatment in adult patients. In September 2016, an additional data application was submitted by Regen BioPharma Inc., for its orphan drug, HemaXelerate. HemaXellerate comprise fat tissue cells of patients and helps induce a response in their body to heal bone marrow and restore the ability to generate new and healthy blood cells. North America holds a major share of the aplastic anemia treatment market, owing to high prevalence of blood disorders. With the presence of major market players, this region is expected to grow further during the forecast period.

Asia-Pacific also has many opportunities for growth in the aplastic anemia treatment market. This region attracts a huge number of global patients as many countries in Asia offer low-cost treatments and surgery options for aplastic anemia.

Key Benefits of the Report

  • This study presents the analytical depiction of the aplastic anemia treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the aplastic anemia treatment market share.
  • The current market is quantitatively analyzed to highlight the aplastic anemia treatment growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Aplastic Anemia Treatment Report

  • Which are the leading players active in the aplastic anemia treatment market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the aplastic anemia treatment market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is aplastic anemia?
  • What are the current and predicted trends of the market?

 Aplastic Anemia Treatment Market Report Highlights

Aspects Details
By Treatment Type
  • Bone Marrow Transfusion/Stem Cell Therapy
  • Blood Transfusion
  • Drug Therapy
    • Alemtuzumab
    • Antithymocyte Globulin
    • Alkylating Agents - Cyclophosphamide
    • Immunosuppressant - Cyclosporine
    • Others
By Disease Type
  • Acquired Aplastic Anemia
  • Inherited Aplastic Anemia
By End User
  • Hospitals
  • Research Institutes
  • Others
By Route of Administration
  • Intravenous
  • Oral
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players Bluebird Bio, Inc., Bayer AG, Octapharma AG, GlaxoSmithKline Plc., Shire, Inc., CSL Limited, Novo Nordisk AS, Novartis Pharmaceuticals Corporation, Kyowa Kirin Co., Ltd., Amgen, Inc., Pfizer Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: APLASTIC ANEMIA TREATMENT MARKET, BY TREATMENT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Type

    • 4.2. Bone Marrow Transfusion/Stem Cell Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Blood Transfusion

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Drug Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

      • 4.4.4. Alemtuzumab

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Antithymocyte Globulin

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Alkylating Agents - Cyclophosphamide

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Immunosuppressant - Cyclosporine

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Others

        • 4.4.4.1. Market Size and Forecast

  • CHAPTER 5: APLASTIC ANEMIA TREATMENT MARKET, BY DISEASE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Type

    • 5.2. Acquired Aplastic Anemia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Inherited Aplastic Anemia

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: APLASTIC ANEMIA TREATMENT MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Research Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: APLASTIC ANEMIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Route Of Administration

    • 7.2. Intravenous

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Oral

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: APLASTIC ANEMIA TREATMENT MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Treatment Type

      • 8.2.3. Market Size and Forecast, By Disease Type

      • 8.2.4. Market Size and Forecast, By End User

      • 8.2.5. Market Size and Forecast, By Route Of Administration

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Aplastic Anemia Treatment Market

        • 8.2.7.1. Market Size and Forecast, By Treatment Type
        • 8.2.7.2. Market Size and Forecast, By Disease Type
        • 8.2.7.3. Market Size and Forecast, By End User
        • 8.2.7.4. Market Size and Forecast, By Route Of Administration

      • 8.2.8. Canada Aplastic Anemia Treatment Market

        • 8.2.8.1. Market Size and Forecast, By Treatment Type
        • 8.2.8.2. Market Size and Forecast, By Disease Type
        • 8.2.8.3. Market Size and Forecast, By End User
        • 8.2.8.4. Market Size and Forecast, By Route Of Administration

      • 8.2.9. Mexico Aplastic Anemia Treatment Market

        • 8.2.9.1. Market Size and Forecast, By Treatment Type
        • 8.2.9.2. Market Size and Forecast, By Disease Type
        • 8.2.9.3. Market Size and Forecast, By End User
        • 8.2.9.4. Market Size and Forecast, By Route Of Administration

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Treatment Type

      • 8.3.3. Market Size and Forecast, By Disease Type

      • 8.3.4. Market Size and Forecast, By End User

      • 8.3.5. Market Size and Forecast, By Route Of Administration

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Aplastic Anemia Treatment Market

        • 8.3.7.1. Market Size and Forecast, By Treatment Type
        • 8.3.7.2. Market Size and Forecast, By Disease Type
        • 8.3.7.3. Market Size and Forecast, By End User
        • 8.3.7.4. Market Size and Forecast, By Route Of Administration

      • 8.3.8. Germany Aplastic Anemia Treatment Market

        • 8.3.8.1. Market Size and Forecast, By Treatment Type
        • 8.3.8.2. Market Size and Forecast, By Disease Type
        • 8.3.8.3. Market Size and Forecast, By End User
        • 8.3.8.4. Market Size and Forecast, By Route Of Administration

      • 8.3.9. Italy Aplastic Anemia Treatment Market

        • 8.3.9.1. Market Size and Forecast, By Treatment Type
        • 8.3.9.2. Market Size and Forecast, By Disease Type
        • 8.3.9.3. Market Size and Forecast, By End User
        • 8.3.9.4. Market Size and Forecast, By Route Of Administration

      • 8.3.10. Spain Aplastic Anemia Treatment Market

        • 8.3.10.1. Market Size and Forecast, By Treatment Type
        • 8.3.10.2. Market Size and Forecast, By Disease Type
        • 8.3.10.3. Market Size and Forecast, By End User
        • 8.3.10.4. Market Size and Forecast, By Route Of Administration

      • 8.3.11. UK Aplastic Anemia Treatment Market

        • 8.3.11.1. Market Size and Forecast, By Treatment Type
        • 8.3.11.2. Market Size and Forecast, By Disease Type
        • 8.3.11.3. Market Size and Forecast, By End User
        • 8.3.11.4. Market Size and Forecast, By Route Of Administration

      • 8.3.12. Russia Aplastic Anemia Treatment Market

        • 8.3.12.1. Market Size and Forecast, By Treatment Type
        • 8.3.12.2. Market Size and Forecast, By Disease Type
        • 8.3.12.3. Market Size and Forecast, By End User
        • 8.3.12.4. Market Size and Forecast, By Route Of Administration

      • 8.3.13. Rest Of Europe Aplastic Anemia Treatment Market

        • 8.3.13.1. Market Size and Forecast, By Treatment Type
        • 8.3.13.2. Market Size and Forecast, By Disease Type
        • 8.3.13.3. Market Size and Forecast, By End User
        • 8.3.13.4. Market Size and Forecast, By Route Of Administration

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Treatment Type

      • 8.4.3. Market Size and Forecast, By Disease Type

      • 8.4.4. Market Size and Forecast, By End User

      • 8.4.5. Market Size and Forecast, By Route Of Administration

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Aplastic Anemia Treatment Market

        • 8.4.7.1. Market Size and Forecast, By Treatment Type
        • 8.4.7.2. Market Size and Forecast, By Disease Type
        • 8.4.7.3. Market Size and Forecast, By End User
        • 8.4.7.4. Market Size and Forecast, By Route Of Administration

      • 8.4.8. Japan Aplastic Anemia Treatment Market

        • 8.4.8.1. Market Size and Forecast, By Treatment Type
        • 8.4.8.2. Market Size and Forecast, By Disease Type
        • 8.4.8.3. Market Size and Forecast, By End User
        • 8.4.8.4. Market Size and Forecast, By Route Of Administration

      • 8.4.9. India Aplastic Anemia Treatment Market

        • 8.4.9.1. Market Size and Forecast, By Treatment Type
        • 8.4.9.2. Market Size and Forecast, By Disease Type
        • 8.4.9.3. Market Size and Forecast, By End User
        • 8.4.9.4. Market Size and Forecast, By Route Of Administration

      • 8.4.10. South Korea Aplastic Anemia Treatment Market

        • 8.4.10.1. Market Size and Forecast, By Treatment Type
        • 8.4.10.2. Market Size and Forecast, By Disease Type
        • 8.4.10.3. Market Size and Forecast, By End User
        • 8.4.10.4. Market Size and Forecast, By Route Of Administration

      • 8.4.11. Australia Aplastic Anemia Treatment Market

        • 8.4.11.1. Market Size and Forecast, By Treatment Type
        • 8.4.11.2. Market Size and Forecast, By Disease Type
        • 8.4.11.3. Market Size and Forecast, By End User
        • 8.4.11.4. Market Size and Forecast, By Route Of Administration

      • 8.4.12. Thailand Aplastic Anemia Treatment Market

        • 8.4.12.1. Market Size and Forecast, By Treatment Type
        • 8.4.12.2. Market Size and Forecast, By Disease Type
        • 8.4.12.3. Market Size and Forecast, By End User
        • 8.4.12.4. Market Size and Forecast, By Route Of Administration

      • 8.4.13. Malaysia Aplastic Anemia Treatment Market

        • 8.4.13.1. Market Size and Forecast, By Treatment Type
        • 8.4.13.2. Market Size and Forecast, By Disease Type
        • 8.4.13.3. Market Size and Forecast, By End User
        • 8.4.13.4. Market Size and Forecast, By Route Of Administration

      • 8.4.14. Indonesia Aplastic Anemia Treatment Market

        • 8.4.14.1. Market Size and Forecast, By Treatment Type
        • 8.4.14.2. Market Size and Forecast, By Disease Type
        • 8.4.14.3. Market Size and Forecast, By End User
        • 8.4.14.4. Market Size and Forecast, By Route Of Administration

      • 8.4.15. Rest of Asia Pacific Aplastic Anemia Treatment Market

        • 8.4.15.1. Market Size and Forecast, By Treatment Type
        • 8.4.15.2. Market Size and Forecast, By Disease Type
        • 8.4.15.3. Market Size and Forecast, By End User
        • 8.4.15.4. Market Size and Forecast, By Route Of Administration

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Treatment Type

      • 8.5.3. Market Size and Forecast, By Disease Type

      • 8.5.4. Market Size and Forecast, By End User

      • 8.5.5. Market Size and Forecast, By Route Of Administration

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Aplastic Anemia Treatment Market

        • 8.5.7.1. Market Size and Forecast, By Treatment Type
        • 8.5.7.2. Market Size and Forecast, By Disease Type
        • 8.5.7.3. Market Size and Forecast, By End User
        • 8.5.7.4. Market Size and Forecast, By Route Of Administration

      • 8.5.8. South Africa Aplastic Anemia Treatment Market

        • 8.5.8.1. Market Size and Forecast, By Treatment Type
        • 8.5.8.2. Market Size and Forecast, By Disease Type
        • 8.5.8.3. Market Size and Forecast, By End User
        • 8.5.8.4. Market Size and Forecast, By Route Of Administration

      • 8.5.9. Saudi Arabia Aplastic Anemia Treatment Market

        • 8.5.9.1. Market Size and Forecast, By Treatment Type
        • 8.5.9.2. Market Size and Forecast, By Disease Type
        • 8.5.9.3. Market Size and Forecast, By End User
        • 8.5.9.4. Market Size and Forecast, By Route Of Administration

      • 8.5.10. UAE Aplastic Anemia Treatment Market

        • 8.5.10.1. Market Size and Forecast, By Treatment Type
        • 8.5.10.2. Market Size and Forecast, By Disease Type
        • 8.5.10.3. Market Size and Forecast, By End User
        • 8.5.10.4. Market Size and Forecast, By Route Of Administration

      • 8.5.11. Argentina Aplastic Anemia Treatment Market

        • 8.5.11.1. Market Size and Forecast, By Treatment Type
        • 8.5.11.2. Market Size and Forecast, By Disease Type
        • 8.5.11.3. Market Size and Forecast, By End User
        • 8.5.11.4. Market Size and Forecast, By Route Of Administration

      • 8.5.12. Rest of LAMEA Aplastic Anemia Treatment Market

        • 8.5.12.1. Market Size and Forecast, By Treatment Type
        • 8.5.12.2. Market Size and Forecast, By Disease Type
        • 8.5.12.3. Market Size and Forecast, By End User
        • 8.5.12.4. Market Size and Forecast, By Route Of Administration

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Pfizer Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Bayer AG

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Novo Nordisk AS

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Shire, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Octapharma AG

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. CSL Limited

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Amgen, Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Novartis Pharmaceuticals Corporation

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. GlaxoSmithKline Plc.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Bluebird Bio, Inc.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Kyowa Kirin Co., Ltd.

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL APLASTIC ANEMIA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR BONE MARROW TRANSFUSION/STEM CELL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR BLOOD TRANSFUSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL APLASTIC ANEMIA TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR ACQUIRED APLASTIC ANEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR INHERITED APLASTIC ANEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL APLASTIC ANEMIA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL APLASTIC ANEMIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL APLASTIC ANEMIA TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL APLASTIC ANEMIA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA APLASTIC ANEMIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. U.S. APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. CANADA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE APLASTIC ANEMIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. ITALY APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 48. ITALY APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ITALY APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 54. UK APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. UK APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 56. UK APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. UK APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC APLASTIC ANEMIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. CHINA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. CHINA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 73. CHINA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. CHINA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. INDIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. INDIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 87. AUSTRALIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 91. THAILAND APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 95. MALAYSIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 99. INDONESIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 103. REST OF ASIA PACIFIC APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 107. LAMEA APLASTIC ANEMIA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 112. BRAZIL APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 116. SOUTH AFRICA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 120. SAUDI ARABIA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 124. UAE APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 125. UAE APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 126. UAE APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 127. UAE APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 128. ARGENTINA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 132. REST OF LAMEA APLASTIC ANEMIA TREATMENT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA APLASTIC ANEMIA TREATMENT, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA APLASTIC ANEMIA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA APLASTIC ANEMIA TREATMENT, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 136. PFIZER INC.: KEY EXECUTIVES
  • TABLE 137. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 139. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. BAYER AG: KEY EXECUTIVES
  • TABLE 142. BAYER AG: COMPANY SNAPSHOT
  • TABLE 143. BAYER AG: OPERATING SEGMENTS
  • TABLE 144. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 145. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. NOVO NORDISK AS: KEY EXECUTIVES
  • TABLE 147. NOVO NORDISK AS: COMPANY SNAPSHOT
  • TABLE 148. NOVO NORDISK AS: OPERATING SEGMENTS
  • TABLE 149. NOVO NORDISK AS: PRODUCT PORTFOLIO
  • TABLE 150. NOVO NORDISK AS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. SHIRE, INC.: KEY EXECUTIVES
  • TABLE 152. SHIRE, INC.: COMPANY SNAPSHOT
  • TABLE 153. SHIRE, INC.: OPERATING SEGMENTS
  • TABLE 154. SHIRE, INC.: PRODUCT PORTFOLIO
  • TABLE 155. SHIRE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 157. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 158. OCTAPHARMA AG: OPERATING SEGMENTS
  • TABLE 159. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 160. OCTAPHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. CSL LIMITED: KEY EXECUTIVES
  • TABLE 162. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 163. CSL LIMITED: OPERATING SEGMENTS
  • TABLE 164. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 165. CSL LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 167. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 168. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 169. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 170. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. NOVARTIS PHARMACEUTICALS CORPORATION: KEY EXECUTIVES
  • TABLE 172. NOVARTIS PHARMACEUTICALS CORPORATION: COMPANY SNAPSHOT
  • TABLE 173. NOVARTIS PHARMACEUTICALS CORPORATION: OPERATING SEGMENTS
  • TABLE 174. NOVARTIS PHARMACEUTICALS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 175. NOVARTIS PHARMACEUTICALS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 177. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 178. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 179. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 180. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. BLUEBIRD BIO, INC.: KEY EXECUTIVES
  • TABLE 182. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
  • TABLE 183. BLUEBIRD BIO, INC.: OPERATING SEGMENTS
  • TABLE 184. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
  • TABLE 185. BLUEBIRD BIO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 186. KYOWA KIRIN CO., LTD.: KEY EXECUTIVES
  • TABLE 187. KYOWA KIRIN CO., LTD.: COMPANY SNAPSHOT
  • TABLE 188. KYOWA KIRIN CO., LTD.: OPERATING SEGMENTS
  • TABLE 189. KYOWA KIRIN CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 190. KYOWA KIRIN CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL APLASTIC ANEMIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL APLASTIC ANEMIA TREATMENT MARKET
  • FIGURE 3. SEGMENTATION APLASTIC ANEMIA TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN APLASTIC ANEMIA TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAPLASTIC ANEMIA TREATMENT MARKET
  • FIGURE 11. APLASTIC ANEMIA TREATMENT MARKET SEGMENTATION, BY BY TREATMENT TYPE
  • FIGURE 12. APLASTIC ANEMIA TREATMENT MARKET FOR BONE MARROW TRANSFUSION/STEM CELL THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. APLASTIC ANEMIA TREATMENT MARKET FOR BLOOD TRANSFUSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. APLASTIC ANEMIA TREATMENT MARKET FOR DRUG THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. APLASTIC ANEMIA TREATMENT MARKET SEGMENTATION, BY BY DISEASE TYPE
  • FIGURE 16. APLASTIC ANEMIA TREATMENT MARKET FOR ACQUIRED APLASTIC ANEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. APLASTIC ANEMIA TREATMENT MARKET FOR INHERITED APLASTIC ANEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. APLASTIC ANEMIA TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. APLASTIC ANEMIA TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. APLASTIC ANEMIA TREATMENT MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. APLASTIC ANEMIA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. APLASTIC ANEMIA TREATMENT MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 23. APLASTIC ANEMIA TREATMENT MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. APLASTIC ANEMIA TREATMENT MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: APLASTIC ANEMIA TREATMENT MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOVO NORDISK AS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOVO NORDISK AS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOVO NORDISK AS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. SHIRE, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. SHIRE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. SHIRE, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. OCTAPHARMA AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. OCTAPHARMA AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. OCTAPHARMA AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. CSL LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. CSL LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. CSL LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. AMGEN, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. AMGEN, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. NOVARTIS PHARMACEUTICALS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. NOVARTIS PHARMACEUTICALS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. NOVARTIS PHARMACEUTICALS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. BLUEBIRD BIO, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. BLUEBIRD BIO, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. BLUEBIRD BIO, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. KYOWA KIRIN CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. KYOWA KIRIN CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. KYOWA KIRIN CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Aplastic Anemia Treatment Market

Start reading.
This Report and over 67,132+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers